Compare Citius Pharmaceuticals Inc (CTXR) vs Invesco NASDAQ 100 ETF (QQQM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Citius Pharmaceuticals Inc vs Invesco NASDAQ 100 ETF — how do they compare? Citius Pharmaceuticals Inc trades at $0.5 (market cap $13.62M), while Invesco NASDAQ 100 ETF trades at $309.39 (market cap $113.40B). The key difference: Invesco NASDAQ 100 ETF is far larger — about 8326× Citius Pharmaceuticals Inc's market cap, and Invesco NASDAQ 100 ETF is trading nearer its 52-week high, Citius Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Citius Pharmaceuticals Inc for 17 Days and Invesco NASDAQ 100 ETF for 54 Days on average.
| CTXR | QQQM | |
|---|---|---|
Market Cap | $13.62M | $113.40B |
Volume | 132,438 | 2,866,236 |
Sector | Health | Broad Market / Factor |
52-Week High | $1.82 | $312.76 |
52-Week Low | $0.48 | $229.87 |
Typical Hold Time | 17 Days | 54 Days |
Enterprise Value | $3.79M | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CTXR trades at $0.4887, down 3.84% with a bearish technical signal despite oversold RSI readings. The company shows early commercial progress with $7.1M revenue in fiscal 2026 from LYMPHIR sales, though profitability remains challenged with negative margins and significant cash burn. Analyst consensus is strongly bullish with 83% buy ratings and a $5.00 price target, reflecting optimism about the oncology drug pipeline.
Investment outlook balances high-risk biotech potential against substantial financial challenges. The primary opportunity lies in LYMPHIR's commercial ramp-up and market adoption, while risks include continued cash burn, execution hurdles, and the speculative nature of early-stage biopharmaceutical development.
QQQM trades at $307.85, down 1.33% today, while maintaining a bullish technical outlook with strong moving average support. The Invesco NASDAQ 100 ETF continues to benefit from institutional accumulation, with QRG Capital Management increasing its position by 207.5% in Q2 2026. Technical indicators show the ETF trading near key resistance at $309, with support established at $305 and $303 levels. The fund's 0.15% expense ratio provides a cost advantage over similar NASDAQ-100 tracking products.
QQQM offers efficient exposure to NASDAQ-100 growth stocks with lower fees, though concentration in technology sectors presents volatility risks. Institutional buying signals confidence in the ETF's long-term prospects despite recent market fluctuations. Investors should monitor technology sector performance and interest rate sensitivity as key drivers of future returns.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Citius Pharmaceuticals Inc
Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.
Read more on CTXR →About Invesco NASDAQ 100 ETF
QQQM is an ETF designed to track the performance of the NASDAQ-100 Index. It provides exposure to the 100 largest non-financial companies listed on the NASDAQ. Positioned as a lower-cost and more long-term-investor-friendly alternative to its peer QQQ, QQQM offers the same fundamental market exposure but typically has a lower share price and is structured to appeal to investors focused on accumulation rather than active trading.
Read more on QQQM →
